Another win for American manufacturing. @AstraZeneca’s $50 billion pledge to expand U.S. manufacturing and R&D shows our tariff strategy at work. The investment will bring high-paying jobs to Virginia, Indiana, Texas, and across the country while hardening our supply chains. Reshoring pharma production is one of our top priorities.